
    
      This a double-blind, placebo-controlled, randomized Phase I/II study of the safety,
      tolerance, pharmacokinetics, and anti-HIV activity of adefovir dipivoxil in HIV-infected
      patients naive to antiretroviral therapy. Patients are randomized to receive a single daily
      dose of adefovir dipivoxil or matching placebo tablet for 4 weeks.
    
  